Low-value breast screenings rare among U.S. veterans

Low-value breast cancer screenings are rare among members of the U.S. Veteran...Read more on AuntMinnie.comRelated Reading: Some minority women more at risk for second breast cancers Fewer breast cancers seen in minority women during COVID-19 Starting biennial breast screening at age 40 saves Black lives Contrast-enhanced mammography can predict underestimated DCIS Chronic stress linked to breast cancer treatment, survival outcomes
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Dr. Laura Esserman answers the door of her bright yellow Victorian home in San Francisco’s Ashbury neighborhood with a phone at her ear. She’s wrapping up one of several meetings that day with her research team at University of California, San Francisco, where she heads the Carol Franc Buck Breast Care Center. She motions me in and reseats herself at a makeshift home office desk in her living room, sandwiched between a grand piano and set of enormous windows overlooking her front yard’s flower garden. It’s her remote base of operations when she’s not seeing patients or operating at the hospita...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Source Type: news
Am Surg. 2021 Sep 29:31348211047205. doi: 10.1177/00031348211047205. Online ahead of print.ABSTRACTBACKGROUND: The COVID-19 pandemic has required new treatment paradigms to limit exposures and optimize hospital resources, including the use of neoadjuvant endocrine therapy (NAET) as bridging therapy for HR+/HER2-invasive tumors and DCIS. While this approach has been used in locally advanced disease, it is unclear how it may affect outcomes in resectable HR+/HER2- tumors.METHODS: Women ≥18 years diagnosed with in situ (Tis) or non-metastatic HR+/HER2- breast cancer from March-May 2019 and 2020 were included. Fisher's exac...
Source: The American Surgeon - Category: Surgery Authors: Source Type: research
Clin Imaging. 2021 Jun 30;80:19-25. doi: 10.1016/j.clinimag.2021.06.035. Online ahead of print.ABSTRACTPartial breast irradiation (PBI) and ultra-hypofractionated whole breast irradiation (uWBI) are contemporary alternatives to conventional and standard hypofractionated whole breast irradiation (WBI), which shorten treatment from 3 to 6 weeks to 1-2 weeks for select patients. PBI and accelerated PBI (APBI) can be delivered with external beam radiation (3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT)), intraoperative radiation (IORT), or brachytherapy. These new radiation techniques o...
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Studies have shown that short-term surgical delays can result in negative impacts on patient outcomes in multiple cancer types as well as in situ carcinoma. Conversely, other cancers such as gastric cancer, advanced melanoma and pancreatic cancer, well-differentiated thyroid cancer, and several genitourinary cancers demonstrated no significant outcome differences with surgical delays.PMID:34142081 | PMC:PMC8208646 | DOI:10.31487/j.COR.2020.06.05
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
During the COVID-19 pandemic, surgical delays have been common for patients with ductal carcinoma in situ (DCIS) and early-stage estrogen receptor-positive (ER+) breast cancer, often in favor of neoadjuvant endocrine therapy (NET). To understand possible ramifications of these delays, we examined the association between time to surgery (TTS), pathological staging and overall survival (OS).
Source: Journal of the American College of Surgeons - Category: Surgery Authors: Tags: Original Scientific Article Source Type: research
During the COVID-19 pandemic, surgical delays have been common for patients with ductal carcinoma in situ (DCIS) and early-stage estrogen receptor-positive (ER+) breast cancer, often in favor of neoadjuvant endocrine therapy (NET). To understand possible ramifications of these delays, we examined the association between time to operation and pathologic staging and overall survival (OS).
Source: Journal of the American College of Surgeons - Category: Surgery Authors: Tags: Original scientific article Source Type: research
Getting the news that you have cancer is overwhelming and frightening. The COVID-19 crisis adds another layer of anxiety. But know this: you can protect yourself from COVID-19 without compromising your cancer treatment. Don’t panic. In the vast majority of cases, a diagnosis of cancer is not an emergency even though it feels like one. There is time to learn about your options and sort out what is right for you. For now, there will be changes to how we do things. Some of the changes will feel disruptive, but many will lead to better, more patient-centered care. Minimizing your chances of exposure to the virus doesn&rs...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | COVID-19 | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Mammography | Radiology | Women